Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19

Posted on May 5, 2020 by Brenton Scott

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.